Rafael Gallardo
Hematology & Oncology · Terre Haute, INNPI 1578670394
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.2% of the total across 219 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 8.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,641 and has fallen 99.6% since, to $16 in 2025. That places this record below the midpoint for hematology & oncology clinicians in IN, where the typical reported total is $3,829.
Across 219 payments — averaging $22.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$405
- Genentech USA, Inc.$379
- Amgen$338
- E.r. Squibb & Sons, L.L.C.$321
- Merck$281
- Pfizer$258
- plus $3K from 32 others
Across 1 payment — averaging $96.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$96
What the payments were for
- Food & beverage$4,56794%
- Education$2806%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 18 | $405 |
| Genentech USA, Inc. | 10 | $379 |
| Amgen | 13 | $338 |
| E.r. Squibb & Sons, L.L.C. | 10 | $321 |
| Merck | 14 | $281 |
| Pfizer | 20 | $258 |
| Novartis | 15 | $254 |
| Sanofi | 9 | $246 |
| Lilly USA, LLC | 11 | $237 |
| Eisai Inc. | 9 | $222 |
| Seagen Inc. | 8 | $211 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $210 |
| Incyte Corporation | 7 | $185 |
| Pharmacyclics LLC, An Abbvie Company | 8 | $163 |
| AstraZeneca(2 entities) | 8 | $141 |
| Tesaro, Inc. | 2 | $137 |
| Clovis Oncology, Inc. | 5 | $89 |
| Daiichi Sankyo Inc. | 5 | $87 |
| Rigel Pharmaceuticals, Inc. | 3 | $78 |
| Bayer | 5 | $78 |
| Boehringer Ingelheim | 4 | $66 |
| Bristol Myers Squibb | 3 | $53 |
| Foundation Medicine, Inc. | 3 | $49 |
| Exelixis Inc. | 2 | $44 |
| Puma Biotechnology, Inc. | 2 | $43 |
| Dova Pharmaceuticals | 2 | $37 |
| Acceleron Pharma, Inc. | 2 | $34 |
| Beigene USA, Inc. | 2 | $29 |
| AbbVie | 2 | $27 |
| Teva Pharmaceuticals USA, Inc. | 2 | $25 |
| Pharmacosmos Therapeutics Inc. | 1 | $21 |
| Gilead | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| GSK | 1 | $16 |
| EUSA Pharma (US) LLC | 1 | $12 |
| Lexicon Pharmaceuticals, Inc. | 1 | $12 |
| Astellas Pharma US Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,847 in reported general payments places this provider in the 50th percentile of 224 hematology & oncology providers in Indiana.
Other hematology & oncology in Terre Haute
- Suresh KunapareddyTerre Haute$30K
- Melhem JabbourTerre Haute$23K
- Ashis ChakrabartiTerre Haute$19K
- Sang HuhTerre Haute$18K
- Richard GaynorIndianapolis$3.7M
- Ruemu BirhirayIndianapolis$3.1M
- Chandler ParkCorydon$661K
- Neel ShahDyer$464K
- Ahad SadiqFort Wayne$430K
- Ajay KandraMadison$408K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.